TITLE

Medical oncology

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS60
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Ultra-high dose epirubicin and ADR-529 induction program preceding tandem alkylator based autologous BMT - durable complete responses in advanced breast are produced,' by A. Langleben et al. Bone marrow transplantation (BMT).
ACCESSION #
9708236656

 

Related Articles

  • Autologous bone marrow transplants for advanced breast cancer.  // HealthFacts;Oct95, Vol. 20 Issue 197, p4 

    Reports on the use of autologous bone marrow transplants as a last resort for women with advanced breast cancer. Lack of safeguards pertaining to the use of the procedure; Assessment of the procedure by ECRI; Transplant as possibly life shortening.

  • Blues review treatment for breast cancer.  // Business Insurance;3/11/96, Vol. 30 Issue 11, p10 

    Reports on the view of a Blue Cross & Blue Shield Association medical advisory panel that bone marrow transplants are effective as treatment for late-stage breast cancer as other therapies. Health insurers' consideration of bone marrow transplant as an experimental therapy for breast cancer and...

  • A LIFESAVER THAT ISN'T. Cole, Judy; Foltz-Gray, Dorothy; Motte, Paula; Schlosberg, Suzanne; Wong, Kimberly // Health (Time Inc. Health);May2000, Vol. 14 Issue 4, p169 

    Declares the ineffectiveness of bone marrow treatment for breast cancer. Results from several clinical trials; Comments from John Durant, former executive vice president of the American Society of Clinical Oncology.

  • Women flock to ABMT for breast cancer without final proof. Smigel, Kara // JNCI: Journal of the National Cancer Institute;7/5/95, Vol. 87 Issue 13, p952 

    Reports on the enthusiasm of women with advanced breast cancer to receive high-dose chemotherapy and autologous bone marrow transplant (ABMT) due to promising results of phase II studies on ABMT. Reason for the lack of women joining the phase II randomization trials despite optimistic...

  • High-Dose Chemotherapy plus Autologous Bone Marrow Transplantation for Metastatic Breast Cancer. Lippman, Marc E. // New England Journal of Medicine;04/13/2000, Vol. 342 Issue 15, p1119 

    Editorial. Comments on the use of high-dose chemotherapy plus autologous bone marrow transplantation for treatment of metastatic breast cancer. Reference to studies, including research by Stadtmauer et al in this issue; Suggestion that this treatment for women with metastatic breast cancer is...

  • Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer. Welch, H Gilbert; Mogielnicki, Juliana // BMJ: British Medical Journal (International Edition);5/4/2002, Vol. 324 Issue 7345, p1088 

    Examines the American experience with autologous bone marrow transplantation (ABMT) for treating breast cancer and its potential relevance to complex cancer therapies in development. History of bone marrow transplantation; Patients in the media; Health services research and ABMT; Insurance...

  • High-dose chemotherapy for breast cancer. Gratwohl, A; Baldomero, H; Rosti, G // Bone Marrow Transplantation;9/15/2000, Vol. 26 Issue 6, p599 

    Comments on an article about the ineffectiveness of high-dose chemotherapy and autologous bone marrow transplantation for treatment of metastatic breast cancer. Criticisms against transplantation procedure; Response of the European Group for Blood and Marrow Transplantation; Number of...

  • News update.  // Materials Management in Health Care;Mar95, Vol. 4 Issue 3, p10 

    Reports that a coalition of 13 medical centers in the United States is developing standards of care for bone marrow transplantation, pediatric cancer, leukemia and breast and colon cancer.

  • Bone marrow/stem cells: no edge in breast cancer. Stephenson, Joan; Stephenson, J // JAMA: Journal of the American Medical Association;5/5/99, Vol. 281 Issue 17, p1576 

    Discusses preliminary results from four studies in the United States and Europe on women with breast cancer. Finding of no difference in survival for patients treated aggressively with high-dose chemotherapy (HDC) followed by bone marrow or peripheral blood stem cell transplant, compared with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics